Skip to main content

Advertisement

Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome

Fig. 3

Analysis of cardiolipin (CL) molecular species in hearts of 7-month-old WT and TazKD mice fed a diet with or without 0.5% BF. a Molecular forms of CL in 7 months old WT mouse heart. Relative distribution of molecular forms of CL as a percentage of total CL content is shown. b Relative expression of Taz in cardiac muscles of WT and TazKD mice with and without BF treatment. c Changes of absolute values of CL in cardiac muscles of WT and TazKD mice with and without BF treatment. d Monolysocardiolipin (MLCL) to CL ratios in cardiac muscles of WT and TazKD mice with and without BF treatment. Numbers in the bars on panels b-d represent the sample size for the corresponding data. e Relative changes of major molecular forms of CL in WT and TazKD mice with and without BF treatment. Data are presented as means ± standard deviation. Sample sizes are shown. Statistically significant differences (p < 0.05) are indicated: *, between untreated and BF-treated WT mice; #, between WT and TazKD mice without BF treatment; ‡, between untreated and BF-treated TazKD mice

Back to article page